# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-20-060149
Filing Date
2020-05-12
Accepted
2020-05-12 16:01:45
Documents
5
Period of Report
2020-06-25
Effectiveness Date
2020-05-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2019153-1_def14a.htm | DEF 14A | 711457
2 | GRAPHIC | tm2019153d1_pc1.jpg | GRAPHIC | 540201
3 | GRAPHIC | tm2019153d1_pc2.jpg | GRAPHIC | 498466
4 | GRAPHIC | tm2019153d1_pc3.jpg | GRAPHIC | 445216
5 | GRAPHIC | tm2019153d1_pc4.jpg | GRAPHIC | 421892
| Complete submission text file | 0001104659-20-060149.txt |  | 3337241

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 20868981
SIC: 2834 Pharmaceutical Preparations